Rapamycin and Infection-related Illness

Conduct a 6-month observational pilot clinical trial to evaluate the safety, monitor the adverse reactions and observe the preliminary effectiveness of medical treatment with oral rapamycin \[Rapamune (Sirolimus)\] in a total of 15 adults, 18 years and older toward preventing and lowering the severity of infectious disease or infection-related illness. Rapamune (Sirolimus) is not approved by the United States Food and Drug Administration (FDA) to prevent and lessen the severity of infection-related illness or infectious disease. Rapamune (Sirolimus) is approved by the FDA for other indications. The main procedures in the study include: * Blood tests to examine cholesterol, lipids, blood platelet counts, inflammation and infection-related health parameters * Questionnaires to examine brain function, mental health, symptoms, overall health status and quality of life * Electrocardiogram (ECG to measure heart function) * Resting diastolic and systolic blood pressure

NCT Number	NCT07054320
Lead Sponsor	Hoskinson Health and Wellness Clinic
Conditions	Infectious Diseases
Enrollment	15 participants
Start Date	2025-08-06
Primary Completion	2026-04 (estimated)
Study Completion	2026-06 (estimated)
Updated on ClinicalTrials.gov	2026-02-17